IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 290 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $14,298 | +9.9% | 300,000 | 0.0% | 0.16% | +4.7% |
| Q1 2024 | $13,005 | -14.3% | 300,000 | 0.0% | 0.15% | -27.5% |
| Q4 2023 | $15,177 | -94.4% | 300,000 | +5616.5% | 0.20% | +6700.0% |
| Q3 2018 | $271,000 | +44.9% | 5,248 | +17.1% | 0.00% | 0.0% |
| Q2 2018 | $187,000 | -5.6% | 4,483 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $198,000 | -15.0% | 4,483 | -3.3% | 0.00% | 0.0% |
| Q4 2017 | $233,000 | -13.1% | 4,634 | -12.3% | 0.00% | -25.0% |
| Q3 2017 | $268,000 | -5.0% | 5,285 | -4.5% | 0.00% | 0.0% |
| Q2 2017 | $282,000 | +17.0% | 5,535 | -7.8% | 0.00% | 0.0% |
| Q1 2017 | $241,000 | -16.0% | 6,002 | +0.0% | 0.00% | -33.3% |
| Q4 2016 | $287,000 | -78.9% | 6,000 | -83.8% | 0.01% | -75.0% |
| Q3 2016 | $1,359,000 | +66.7% | 37,100 | +6.0% | 0.02% | +50.0% |
| Q2 2016 | $815,000 | -63.1% | 35,000 | -35.8% | 0.02% | -62.8% |
| Q1 2016 | $2,207,000 | -53.1% | 54,500 | -28.3% | 0.04% | -47.6% |
| Q4 2015 | $4,710,000 | – | 76,060 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
| BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
| TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
| DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
| Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
| Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
| ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
| Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
| PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
| Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |